Bayer saw group sales grow by 15% in the second quarter to €9.2 billion, and confirmed its outlook for the full year. This comes despite Bayer downwardly revising its sales forecast for its healthcare division following the "unexpected" market entry of a generic competitor to the contraceptive Yaz (drospirenone plus ethinylestradiol) in the US in June which has sparked a flurry of litigation activity by Bayer (scripintelligence.com, 30 June 2010).
Yaz sales dropped by 15% in the quarter and Bayer now expects sales in the pharmaceutical segment to remain flat...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?